Chief Financial Officer
“TScan has assembled an ideal team, world-class scientific founders and advisors plus experienced investors to capture the immense promise of the TCR therapeutics.”
Robert Crane is the Chief Financial Officer of TScan Therapeutics. Bob has over 30 years of experience in the life sciences industry including therapeutics, medical devices and diagnostics. He has served as Chief Financial Officer at a variety of companies including Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline plc.; I-STAT Corporation, Inc., which was acquired by Abbott Laboratories; InKine Pharmaceutical Company, Inc., which was acquired by Salix, Inc.; Seragen, Inc., which was acquired by Ligand Pharmaceuticals, Inc.; deCODE which was acquired by Amgen and GI Dynamics. Robert has held senior roles at public and private firms in the U.S. and Europe, and served as Chief Financial Officer at four U.S. public companies. Robert has been responsible for several IPOs and numerous financings with proceeds of approximately $1 billion as well as many partnerships and collaborations. Robert was previously a partner in the venture capital firm, Montgomery Ventures and Chairman of the American Bicycle Group. Robert holds a B.S. in mechanical engineering from the Massachusetts Institute of Technology and an MBA from Stanford University.
Bob competes in IronMan triathlons in the summer and seeks the steepest slopes of Jackson Hole, Snowbird and Whistler in the winter.